Phase I, Open Label Trial to Explore Safety of Combining BIBW 2992 and Radiotherapy With or Without Temozolomide in Newly Diagnosed GBM
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Afatinib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 15 Sep 2017 Status changed from active, no longer recruiting to completed.
- 08 May 2017 Planned End Date changed from 1 Apr 2017 to 29 Sep 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History